SRPT
Sarepta Therapeutics, Inc.
Phase 3
Estimated
Eteplirsen
Muscular Dystrophy, Duchenne
T-minus 26 days
Oct 31, 2026
ClinicalTrials.gov
verified 3mo ago
Countdown card →